NCT05517603View on ClinicalTrials.gov

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

February 28, 2023

Primary Completion Date

April 8, 2024

Study Completion Date

April 8, 2024

Conditions
Spinal and Bulbar Muscular AtrophyKennedy's Disease
Interventions
DRUG

AJ201

Administered orally

DRUG

Placebo

Administered orally

Trial Locations (6)

20814

National Institutes of Health, Bethesda

32224

Mayo Clinic, Jacksonville

55905

Mayo Clinic, Rochester

63110

Washington University in St. Louis, St Louis

92868

University of California, Irvine, Orange

94304

Stanford University, Palo Alto

Sponsors
All Listed Sponsors
lead

AnnJi Pharmaceutical Co., Ltd.

INDUSTRY

NCT05517603 - A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients | Biotech Hunter | Biotech Hunter